MedTrace Logo

Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.

NCT07645430 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-06-12

No results posted yet for this study

Summary

The primary objective of this study was to evaluate the change in serum interferon gamma and Interleukin-15 levels before and after use of oral drug baricitinib therapy. Venous blood samples (5 mL) were collected from each participant at baseline and at six months.

Conditions

Interventions

DRUG

Baricitinib 4 MG Oral Tablet

All cases will use oral Baricitinab 4mg daily dose for six months.

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Amal Youssif Habashy, MD · Benha University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-01-01
Completion
2026-06-09

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07645430 on ClinicalTrials.gov